Search Results - "Yu, Tiffany M"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review by HORNBERGER, John, ALVARADO, Michael D, CHIEN, Rebecca, GUTIERREZ, Hialy R, YU, Tiffany M, GRADISHAR, William J

    “…At least 14 stratifiers exist to assess recurrence risk, chemotherapy response, and overall survival (OS) in women with early-stage breast cancer (ESBC). These…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening by Harper, Diane M, Anderson, Rye J, Baker, Ed, Yu, Tiffany M

    “…The first biomarker-based cervical cancer screening test, p16/Ki-67 dual-stained cytology (DS), has been clinically validated and approved in the United States…”
    Get full text
    Journal Article
  4. 4

    Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non–Small-cell Lung Cancer: A Single-center Analysis by Yu, Tiffany M., Morrison, Carl, Gold, Edward J., Tradonsky, Alison, Layton, Andrew J.

    Published in Clinical lung cancer (01-01-2019)
    “…First-line targeted therapies have been developed for advanced non–small-cell lung cancer (NSCLC). However, small biopsy samples pose a challenge to testing…”
    Get full text
    Journal Article
  5. 5

    Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer by Alberts, Steven R., Yu, Tiffany M., Behrens, Robert J., Renfro, Lindsay A., Srivastava, Geetika, Soori, Gamini S., Dakhil, Shaker R., Mowat, Rex B., Kuebler, John P., Kim, George P., Mazurczak, Miroslaw A., Hornberger, John

    Published in PharmacoEconomics (01-12-2014)
    “…Background Prior economic analysis that compared the 12-gene assay to published patterns of care predicted the assay would improve outcomes while lowering…”
    Get full text
    Journal Article
  6. 6

    Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non–Small Cell Lung Cancer by Yu, Tiffany M., Morrison, Carl, Gold, Edward J., Tradonsky, Alison, Arnold, Renée J.G.

    Published in Value in health (01-11-2018)
    “…Genetic testing for nonsquamous advanced non–small cell lung cancer (aNSCLC) is recommended to guide first-line therapy. Activating mutations can be identified…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Cost-effectiveness of adding Endocuff ® to standard colonoscopies for interval colorectal cancer screening by Yu, Tiffany M, Tradonsky, Alison, Tang, Jun, Arnold, Renée Jg

    Published in ClinicoEconomics and outcomes research (01-01-2019)
    “…Higher screening colonoscopy adenoma detection rates (ADRs) correlate with reduced risk of interval colorectal cancer (CRC). The Endocuff device has been shown…”
    Get full text
    Journal Article
  9. 9

    Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA by Yu, Tiffany M, Dugel, Pravin U, Haller, Julia A, Kaiser, Peter K, Arnold, Renée JG

    “…Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea ). This analysis used…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12